mark cuban pharmacy semaglutide Cuban's Cost Plus partners with telehealth firm to offer employers obesity care drugs Mark Cuban's Cost Plus Drug

Summary: Retatrutide FDA Status Retatrutide is not FDA-approved and won't be for at least another year It's in Phase 3 trials (TRIUMPH program) with results expected in late 2026 FDA approval is projected for 20272028 Phase 2 data showed 24.2% weight loss , better than any approved GLP-1 medication Current access: clinical trials (free), compounded retatrutide ($200$500/mo), or research peptides ($150$500/mo) When approved, retatrutide will be the first triple-agonist obesity medication on the market References Jastreboff AM, Aronne LJ, Ahmad NN, et al

What is obesity, and why must we be concerned

50 g of protein was digested overnight at 37 C using Lys-C (10 l/1 mg protein) and trypsin (20 l/1 mg protein) and stopped on the next day by addition of 1 % (v/v) trifluoroacetic acid (TFA)

21 , e70033 (2025)

For year-round use, these rare events reinforce the importance of proper hydration, regular health monitoring, and communication with a healthcare professional if anything feels off